Fortress Biotech, Inc. (FBIO)
$1.95-7.58%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $65M
- Beta
- 1.25
- P/E (TTM)
- 0.60
- Short % float
- 21.21%
- Days to cover
- 18.4
- SI change
- -4.1%
- 1W
- -4.88%
- 1M
- -22.92%
- vs SPY 1W
- -4.74%
- vs SPY 1M
- -25.43%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 28
- GROWTH
- 40
- GARP
- 10
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC62.1%
REV YoY-
ROE103.5%
EPS YoY-
ROA35.3%
GROSS63
OP-43
NET163
[VALUATION]
P/E TTM0.60
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.38
P/FCF-
EV/EBITDA-0.42
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E39.47
ALTMAN Z-
CURR RATIO3.96
ND/EBITDA-
BETA1.25
Company news
FAQ
- What is LOPJLB’s current signal on FBIO?
- LOPJLB’s latest quantitative signal on Fortress Biotech, Inc. (FBIO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is FBIO in?
- Fortress Biotech, Inc. (FBIO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Fortress Biotech, Inc. (FBIO) do?
- Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe ca…